V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Summary

The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females

Timeline

Start

2006-12-11

Primary completion

2009-09-18

Completion

2009-09-18

Publications

• Murata S, Shirakawa M, Sugawara Y, Shuto M, Sawata M, Tanaka Y. Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants. Papillomavirus Res. 2020 Dec;10:100205. doi: 10.1016/j.pvr.2020.100205. Epub 2020 Aug 19.

Drugs

Indications